USPTO serial 79278341
DEVATIS
Reviewed by CopyMark Law Group
Reg. 6127100Status 706Renewal
- Filing date
- Status date
- Registration date
- Aug 18, 2020
- Examiner
- HARMON, RAYMOND E
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with DEVATIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $425
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
TR-34303 ISTANBUL, TR
TR-34303 ISTANBUL, TR
KÜÇÜKÇEKMECE/ISTANBUL, TR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nicholas D. Wells
Nicholas D. Wells Legends Law Group, PLLC330 MAIN ST.KAYSVILLE, UT 84037United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in treating by inhibiting the growth of tumors, as antiparasitics, and for treatment of the nervous systems, orthopedic and musculoskeletal disease, respiratory disease, genital and urologic disease, endocrinology disease, cardiovascular disease, dermatological disease, metabolic disease, gastrointestinal disease, hormonal diseases, ophthalmological disease, cancer and diseases of the blood, and for use in treating immune function, psychiatric disorders, fatigue, and sexual disfunction; veterinary preparations for use in treating by inhibiting the growth of tumors, as antiparasitics, and for treatment of the nervous systems, orthopedic and musculoskeletal disease, respiratory disease, genital and urologic disease, endocrinology disease, cardiovascular disease, dermatological disease, metabolic disease, gastrointestinal disease, hormonal diseases, ophthalmological disease, cancer and diseases of the blood, and for use in treating immune function, psychiatric disorders, fatigue, and sexual disfunction; sanitary preparations for medical purposes; dietetic foods namely, food supplements and dietary supplements adapted for medical use; dietetic sugar for medical use; food for babies; dietary supplements for humans and animals; medical plasters, materials for dressings; material for stopping teeth, dental wax; all purpose disinfectants; preparations for destroying vermin; fungicides, herbicides | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 19, 2026 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Aug 19, 2026 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Aug 14, 2026 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Aug 13, 2026 | PR71 | POST REGISTRATION ACTION MAILED - SEC.71 | — |
| Aug 10, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 11, 2026 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Mar 26, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 18, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Dec 19, 2022 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Nov 6, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 18, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 14, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 9, 2020 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Dec 9, 2020 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Nov 18, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 13, 2020 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Aug 18, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 2, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 2, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 13, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 23, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 22, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 22, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 22, 2020 | ALIE | ASSIGNED TO LIE | — |
| Apr 18, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 10, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 20, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 20, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 4, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 3, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 24, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 18, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 14, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 13, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |